Results 71 to 80 of about 21,169 (256)

PSMA-PET/CT-Positive Paget Disease in a Patient with Newly Diagnosed Prostate Cancer: Imaging and Bone Biopsy Findings

Case Reports in Urology, 2017
A 67-year-old man diagnosed with Gleason score 4+5=9 clinically localized prostate cancer with 68Ga-labeled prostate-specific membrane antigen-targeted ligand positron emission tomography/computed tomography (PSMA-PET/CT) positive Paget bone disease is ...
Michael Froehner, Marieta Toma, Klaus Zöphel, Vladimir Novotny, Michael Laniado, Manfred P. Wirth   +5 more
doaj   +1 more source

LU-177-PSMA TREATMENT FOR METASTATIC PROSTATE CANCER – CASE EXAMPLES OF MIRACLE RESPONSES

Вестник урологии, 2018
Prostate specific membrane antigen (PSMA) is expressed in unfavorable prostate cancer. PSMA is basis for new diagnostics and theranostics. 177Lu-PSMA radioligand therapy is mainly used for patients with endstage prostate cancer. This report describes two
K. Kairemo, T. Joensuu
doaj   +1 more source

Prostate specific membrane antigen (PSMA) expression in non-small cell lung cancer

PLOS ONE, 2017
PSMA (prostate-specific membrane antigen) is overexpressed in prostate cancer cells and is reported to be a promising target for antibody-based radioligand therapy in patients with metastasized prostate cancer. Since PSMA expression is not restricted to prostate cancer, the underlying study investigates PSMA expression in non-small cell lung cancer ...
Schmidt, Lars Henning, Heitkötter, Birthe Franziska, Schulze, Arik Bernard, Schliemann, Christoph, Steinestel, Konrad Ernst, Trautmann, Marcel, Marra, Alessandro, Hillejan, Ludger, Mohr, Michael, Evers, Georg Heribert, Wardelmann, Eva, Rahbar, Kambiz, Görlich, Dennis, Lenz, Georg, Berdel, Wolfgang E., Hartmann, Wolfgang, Wiewrodt, Rainer Gerhard, Huss, Sebastian   +17 more
openaire   +5 more sources

Boron Neutron Capture Therapy at a Crossroads: Translational Gap and Emerging Delivery Agents

Chemistry – A European Journal, EarlyView.
This review surveys recent advances in boron delivery agents for BNCT, emphasizing the shift from classical small molecules to multifunctional nanocarriers and theranostic systems. By integrating targeting, imaging, and therapy, next‐generation boron compounds aim to bridge the gap between (bio)chemical innovation and clinical translation.
Christoph Selg, Evamarie Hey‐Hawkins
wiley   +1 more source

Diagnosing small bowel carcinoid tumor in a patient with oligometastatic prostate cancer imaged with PSMA-Targeted [18F]DCFPyL PET/CT: Value of the PSMA-RADS-3D Designation

Urology Case Reports, 2018
Radiotracers targeting prostate-specific membrane antigen (PSMA), including [18F]DCFPyL, have been extensively investigated as a means to image prostate cancer more accurately.
Eugene Shenderov, Michael A. Gorin, Seohyun Kim, Pamela T. Johnson, Mohamad E. Allaf, Alan W. Partin, Martin G. Pomper, Emmanuel S. Antonarakis, Kenneth J. Pienta, Steven P. Rowe   +9 more
doaj   +1 more source

Phosphorescent Iridium Hydrazinonicotinic Acid (HYNIC) Complexes That Bind to Prostate Specific Membrane Antigen: Potential Photodynamic Therapy of Prostate Cancer

Chemistry – A European Journal, EarlyView.
A phosphorescent iridium(III) complex has been prepared with a 6‐hydrazinonicotinic acid (HYNIC) ligand tethered to a lysine‐ureido‐glutamatic acid pharmacophore, which binds to an enzyme, called prostate‐specific membrane antigen (PSMA), which is overexpressed in prostate cancer.
La'El Kimchi, Emily R. McGowan, Katherine A. Morgan, Jonathan M. White, Trevor A. Smith, Stacey E. Rudd, Paul S. Donnelly   +6 more
wiley   +1 more source

Clinical Advantages of Positron Emission Tomography/Computed Tomography and Positron Emission Tomography/Magnetic Resonance in Radiotherapy: A Narrative Review

iRADIOLOGY, EarlyView.
Review the clinical application of PET multimodal imaging and compare its clinical advantages. ABSTRACT Positron emission tomography (PET)–based multimodal imaging, including PET/computed tomography (PET/CT) and PET/magnetic resonance (PET/MR), plays an increasingly important role in precision radiotherapy by integrating metabolic and anatomical ...
Yingze Fu, Jyh‐Cheng Chen, Zhongying Ma, Junchi Ma, Jianfeng Qiu   +4 more
wiley   +1 more source

Production of Nanobodies against Prostate-Specific Membrane Antigen (PSMA) Recognizing LnCaP Cells

The International Journal of Biological Markers, 2014
Prostate cancer is the most common type of cancer in men. The antibody-mediated therapy for cancer treatment depends on the identification of selected molecular targets. The prostate-specific membrane antigen (PSMA) is a potential molecular target in prostate cancer and is abundantly expressed in this type of cancer.
Hamed, Zare, Masoumeh, Rajabibazl, Iraj, Rasooli, Walead, Ebrahimizadeh, Hamid, Bakherad, Leila Safaiee, Ardakani, Seyed Latif Mousavi, Gargari   +6 more
openaire   +2 more sources

Australian Society of Medical Imaging and Radiation Therapy Image Registration in Radiation Therapy Position Paper

Journal of Medical Radiation Sciences, EarlyView.
The ASMIRT Image Registration Working Party outlines the critical role of radiation therapists in performing, assessing and documenting rigid and deformable image registration across treatment planning, delivery and adaptive workflows. The position paper emphasises consistent nomenclature, robust QA processes, strong collaboration with diagnostic ...
Tamara Barry, Huong Nguyen, Laurel Schmidt, Kate Stewart, Nigel Anderson   +4 more
wiley   +1 more source

Molecular theranostics: principles, challenges and controversies

Journal of Medical Radiation Sciences, Volume 72, Issue 1, Page 156-164, March 2025.
Molecular theranostics offers a powerful tool to drive precision medicine in nuclear oncology. While theranostics is not a new principle in nuclear medicine, recent advances in instrumentation and radiopharmacy have driven a reinvigoration and a broader suite of applications.
Geoffrey Currie
wiley   +1 more source